Efficacy and patient selection of consolidative thoracic radiotherapy following chemoimmunotherapy in ES-SCLC (opens in new tab)

BackgroundDespite significant progress with immunotherapy in extensive-stage small-cell lung cancer (ES-SCLC), progression-free survival (PFS) remains limited, and relapse is common. Whether consolidative thoracic radiotherapy (cTRT) administered after first-line chemoimmunotherapy offers additional clinical benefit remains uncertain, and the lack of clear patient selection criteria further restricts its application in real-world.MethodsES-SCLC patients who received first-line PD-1/PD-L1 inhi...